CREST II Secondary Outcomes
I cannot provide information about CREST II secondary outcomes because the evidence provided does not contain any data from the CREST II trial. The documents reference only the original CREST trial (Carotid Revascularization Endarterectomy versus Stenting Trial), not CREST II.
What the Evidence Contains
The available evidence discusses the original CREST trial design and outcomes:
The original CREST trial's primary outcome was the occurrence of any stroke, myocardial infarction, or death during the 30-day peri-procedural period, and ipsilateral stroke during follow-up of up to four years 1
The original CREST trial's secondary outcomes included restenosis and health-related quality of life 1
A secondary analysis of CREST examined the composite endpoint of restenosis or occlusion at 2 years, defined as a reduction in diameter of the target artery of at least 70% (peak systolic velocity ≥3.0 m/s) 2
Additional secondary aims of the original CREST included contrasting efficacy of CAS versus CEA in men and women, restenosis rates, health-related quality of life, and cost effectiveness 3
Important Distinction
CREST (2010) and CREST II are separate trials. The evidence provided contains extensive information about CREST but no information about CREST II. To answer your question about CREST II secondary outcomes, I would need access to the CREST II trial protocol or published results, which are not included in the provided evidence.